JP6456143B2 - カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物 - Google Patents

カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物 Download PDF

Info

Publication number
JP6456143B2
JP6456143B2 JP2014547135A JP2014547135A JP6456143B2 JP 6456143 B2 JP6456143 B2 JP 6456143B2 JP 2014547135 A JP2014547135 A JP 2014547135A JP 2014547135 A JP2014547135 A JP 2014547135A JP 6456143 B2 JP6456143 B2 JP 6456143B2
Authority
JP
Japan
Prior art keywords
formula
compound
reaction
mixture
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014547135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500335A5 (https=
JP2015500335A (ja
Inventor
ルッソ，ドメニコ
アルノ キス，ラズロ
アルノ キス，ラズロ
ブルーノ ライス ワノン，ジョルジュ
ブルーノ ライス ワノン，ジョルジュ
アレクサンダー リーマス，デヴィッド
アレクサンダー リーマス，デヴィッド
エスゼニー，ティボル
ジメルマン，アクセル
シュルメル，ビョルン
クライス，ミカエル
ロイター，クラウス
Original Assignee
ノヴィファーマ，エス．アー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48612903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6456143(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1121413.7A external-priority patent/GB201121413D0/en
Priority claimed from GBGB1201758.8A external-priority patent/GB201201758D0/en
Application filed by ノヴィファーマ，エス．アー． filed Critical ノヴィファーマ，エス．アー．
Publication of JP2015500335A publication Critical patent/JP2015500335A/ja
Publication of JP2015500335A5 publication Critical patent/JP2015500335A5/ja
Application granted granted Critical
Publication of JP6456143B2 publication Critical patent/JP6456143B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2014547135A 2011-12-13 2012-12-12 カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物 Active JP6456143B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201161570141P 2011-12-13 2011-12-13
GBGB1121413.7A GB201121413D0 (en) 2011-12-13 2011-12-13 Chemical compounds and processes
GB1121413.7 2011-12-13
US61/570,141 2011-12-13
US201261593625P 2012-02-01 2012-02-01
GBGB1201758.8A GB201201758D0 (en) 2012-02-01 2012-02-01 Chemical compounds and processes
GB1201758.8 2012-02-01
US61/593,625 2012-02-01
US201261718589P 2012-10-25 2012-10-25
US61/718,589 2012-10-25
PCT/PT2012/000048 WO2013089573A1 (en) 2011-12-13 2012-12-12 Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017207738A Division JP6721558B2 (ja) 2011-12-13 2017-10-27 カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物

Publications (3)

Publication Number Publication Date
JP2015500335A JP2015500335A (ja) 2015-01-05
JP2015500335A5 JP2015500335A5 (https=) 2016-02-12
JP6456143B2 true JP6456143B2 (ja) 2019-01-23

Family

ID=48612903

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014547135A Active JP6456143B2 (ja) 2011-12-13 2012-12-12 カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物
JP2017207738A Active JP6721558B2 (ja) 2011-12-13 2017-10-27 カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物
JP2019214566A Withdrawn JP2020059729A (ja) 2011-12-13 2019-11-27 カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017207738A Active JP6721558B2 (ja) 2011-12-13 2017-10-27 カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物
JP2019214566A Withdrawn JP2020059729A (ja) 2011-12-13 2019-11-27 カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物

Country Status (15)

Country Link
US (2) US9126988B2 (https=)
EP (2) EP2791134B1 (https=)
JP (3) JP6456143B2 (https=)
BR (1) BR112014014341A2 (https=)
CA (2) CA3088684C (https=)
CY (1) CY1122580T1 (https=)
DK (1) DK2791134T3 (https=)
ES (2) ES2758659T3 (https=)
HR (1) HRP20192133T8 (https=)
HU (1) HUE047856T2 (https=)
PL (1) PL2791134T3 (https=)
PT (2) PT2791134T (https=)
RS (1) RS59666B1 (https=)
SI (1) SI2791134T1 (https=)
WO (1) WO2013089573A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1907382T3 (pl) 2005-07-26 2016-01-29 Bial Portela & Ca Sa Pochodne nitrokatecholowe jako inhibitory COMT
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
BRPI0721213B1 (pt) 2007-01-31 2021-11-09 Bial - Portela & Ca, S.A. Uso de nitrocatecóis substituídos, e embalagem
WO2009116882A1 (en) 2008-03-17 2009-09-24 Portela & Ca., S.A. Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol
PT2413912T (pt) 2009-04-01 2019-06-11 Bial Portela & Ca Sa Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
JP6456143B2 (ja) * 2011-12-13 2019-01-23 ノヴィファーマ，エス．アー． カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
GB2563858A (en) * 2017-06-27 2019-01-02 Azad Pharmaceutical Ingredients Ag New route of synthesis for opicapone
US20210087183A1 (en) * 2017-12-18 2021-03-25 Unichem Laboratories Ltd Process for the preparation of opicapone and intermediates thereof
EP3860602A1 (en) * 2018-10-05 2021-08-11 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
WO2020072886A1 (en) 2018-10-05 2020-04-09 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
CN109529881A (zh) * 2018-11-12 2019-03-29 刘晓菊 一种治疗帕金森药物用中间体5-硝基香草酸的制备方法
WO2021182981A1 (en) 2020-03-13 2021-09-16 BIAL - PORTELA & Cª, S.A. Micronised opicapone
TW202200138A (zh) * 2020-05-26 2022-01-01 日商小野藥品工業股份有限公司 包含奧匹卡朋（ｏｐｉｃａｐｏｎｅ）之錠劑
GB202011709D0 (en) 2020-07-28 2020-09-09 Bial Portela & Ca Sa Solid dispersion of opicapone
GB202016425D0 (en) 2020-10-16 2020-12-02 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
EP4262798A1 (en) 2020-12-17 2023-10-25 Bial-Portela & CA, S.A. Treatment regimens for early idiopathic parkinson's disease
CN112375014A (zh) * 2020-12-17 2021-02-19 重庆柳江医药科技有限公司 一种奥匹卡朋工艺杂质及制备方法和用途
US20240300930A1 (en) * 2021-02-26 2024-09-12 Msn Laboratories Private Limited, R&D Center Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide
CN113292489B (zh) * 2021-06-16 2022-08-30 泓博智源(开原)药业有限公司 二氯代二烷基烟腈的制备方法
GB202204798D0 (en) 2022-04-01 2022-05-18 Bial Portela & Ca Sa Prodrugs of opicapone
GB202212082D0 (en) 2022-08-18 2022-10-05 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
GB202219669D0 (en) 2022-12-23 2023-02-08 Bial Portela & Ca Sa Processes and intermediates for synthesising opicapone
EP4719374A1 (en) 2023-05-25 2026-04-08 Bial-Portela & CA, S.A. Treatment regimens for early idiopathic parkinson's disease
EP4727649A1 (en) * 2023-06-19 2026-04-22 Medichem, S.A. Process for preparing opicapone
AU2024288001A1 (en) 2023-07-11 2026-01-15 Tay Therapeutics Limited Compounds comprising a naphthyridine or pyridopyrimidine core as ptc read-through agents
CN119775271A (zh) * 2024-12-31 2025-04-08 南京海纳医药科技股份有限公司 一种奥吡卡朋粗品的精制方法
CN120081837A (zh) * 2025-02-14 2025-06-03 江苏天士力帝益药业有限公司 一种低单杂高纯度的奥匹卡朋中间体05的制备方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1532178A (en) 1921-07-25 1925-04-07 Louis A Godbold Lubricator
FR1260080A (fr) 1960-03-22 1961-05-05 Materiel De Forage Soc De Fab Trépan à molettes étanche
US3647809A (en) 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
US4022901A (en) 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
US4264573A (en) 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
US4386668A (en) 1980-09-19 1983-06-07 Hughes Tool Company Sealed lubricated and air cooled rock bit bearing
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
YU213587A (en) 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
DE3840954A1 (de) 1988-12-05 1990-06-07 Shell Int Research Herstellung von 2-chlornicotinsaeureestern
US5206372A (en) 1990-06-05 1993-04-27 Shell Research Limited Preparation of 2-chloropyridine derivatives
ES2066092T3 (es) 1990-11-29 1995-03-01 Wei Ming Pharmaceutical Mfg Co Coadyuvante para la formacion directa de comprimidos.
EP0619814A1 (en) 1991-12-31 1994-10-19 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
FR2730322B1 (fr) 1995-02-02 1997-04-30 Imago Monture de lunettes metallique
DE19628617A1 (de) 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
US6206110B1 (en) 1996-09-09 2001-03-27 Smith International, Inc. Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit
JP2002526482A (ja) 1998-09-18 2002-08-20 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
GB2344819A (en) 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
KR100875222B1 (ko) 1999-08-19 2008-12-19 아스트라제네카 아베 헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
FI20000635A0 (fi) 2000-03-17 2000-03-17 Orion Yhtymae Oyj COMT-inhibiittoreiden käyttö analgeettina
SE0001438D0 (sv) 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
GB2363792A (en) 2000-06-21 2002-01-09 Portela & Ca Sa Nitrocatechols
CN1166626C (zh) 2000-08-30 2004-09-15 李凌松 三或四取代苯基化合物、其制备方法及应用
JP2004532611A (ja) 2000-11-28 2004-10-28 ザイモジェネティクス，インコーポレイティド サイトカイン受容体ｚｃｙｔｏｒ１９
WO2002051442A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Concomitant drugs
US20040097555A1 (en) 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
MXPA03007513A (es) 2001-02-21 2004-07-30 Nps Pharma Inc Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
WO2002096867A2 (en) 2001-05-30 2002-12-05 Lg Biomedical Institute Inhibitors of protein kinase for the treatment of disease
JP2005504014A (ja) 2001-06-08 2005-02-10 サイトビア インコーポレイテッド カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された３−アリール−５−アリール−［１，２，４］−オキサジアゾール類および類似体、並びにその使用法
PT1408964E (pt) 2001-07-26 2007-05-31 Merck Patent Gmbh Utilização de 2-5-(4-fluorofenil) -3-piridilmetilaminometil-cromano e de seus sais fisiologicamente aceitáveis.
JP4379853B2 (ja) 2001-10-05 2009-12-09 惠民製藥股▲分▼有限公司 直接錠剤化用調合物および補助剤の調合方法
CN100364531C (zh) 2002-12-18 2008-01-30 西托维亚公司 3,5－二取代－[1,2,4]－二唑及类似物和其用途
WO2005006945A2 (en) 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
WO2005013982A1 (en) 2003-08-06 2005-02-17 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7300406B2 (en) 2003-09-30 2007-11-27 Carter Vandette B Medical examination apparatus
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005105780A2 (en) 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
US20060173074A1 (en) 2004-11-10 2006-08-03 Juha Ellmen Treatment of restless legs syndrome
WO2006061697A1 (en) 2004-12-06 2006-06-15 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
WO2006071184A1 (en) 2004-12-28 2006-07-06 Astrazeneca Ab Aryl sulphonamide modulators
US20080051441A1 (en) 2004-12-28 2008-02-28 Astrazeneca Ab Aryl Sulphonamide Modulators
US8017631B2 (en) 2005-04-26 2011-09-13 Neurosearch A/S Oxadiazole derivatives and their medical use
US20060257473A1 (en) 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
US7553964B2 (en) 2005-06-03 2009-06-30 Abbott Laboratories Cyclobutyl amine derivatives
JP2007024970A (ja) 2005-07-12 2007-02-01 Miyakawa:Kk 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置
US20090000437A1 (en) 2005-07-14 2009-01-01 Provo Craft And Novelty, Inc. Methods for Cutting
PL1907382T3 (pl) 2005-07-26 2016-01-29 Bial Portela & Ca Sa Pochodne nitrokatecholowe jako inhibitory COMT
FR2889525A1 (fr) 2005-08-04 2007-02-09 Palumed Sa Nouveaux derives de polyquinoleines et leur utilisation therapeutique.
US20070048384A1 (en) 2005-08-26 2007-03-01 Joerg Rosenberg Pharmaceutical compositions
EP1954137A4 (en) 2005-11-18 2008-12-17 Janssen Pharmaceutica Nv 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE
WO2007063946A1 (ja) 2005-11-30 2007-06-07 Fujifilm Ri Pharma Co., Ltd. アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
GB0606774D0 (en) 2006-04-03 2006-05-10 Novartis Ag Organic compounds
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
BRPI0721213B1 (pt) 2007-01-31 2021-11-09 Bial - Portela & Ca, S.A. Uso de nitrocatecóis substituídos, e embalagem
KR101669432B1 (ko) 2007-08-27 2016-10-26 다트 뉴로사이언스 (케이만) 엘티디. 치료적 이속사졸 화합물
MX2010009043A (es) 2008-02-28 2010-10-25 Bial Portela & Ca Sa Composicion farmaceutica para farmacos poco solubles.
WO2009116882A1 (en) * 2008-03-17 2009-09-24 Portela & Ca., S.A. Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,3] oxadiazol-5-yl] -3-nit robenzene-1, 2-diol
ES2723729T3 (es) 2008-07-29 2019-08-30 Bial Portela & Ca Sa Régimen de administración de nitrocatecoles
BRPI1016132B8 (pt) 2009-04-01 2021-05-25 Bial Portela & Ca Sa composição, formulação farmacêutica, processo de obtenção de uma formulação farmacêutica estável
PT2413912T (pt) 2009-04-01 2019-06-11 Bial Portela & Ca Sa Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir
EA026419B1 (ru) 2010-03-04 2017-04-28 Орион Корпорейшн Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
JP6456143B2 (ja) * 2011-12-13 2019-01-23 ノヴィファーマ，エス．アー． カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物

Also Published As

Publication number Publication date
HRP20192133T8 (hr) 2021-02-19
US20160009700A1 (en) 2016-01-14
US20140350057A1 (en) 2014-11-27
CA2858025C (en) 2020-09-22
WO2013089573A1 (en) 2013-06-20
US9630955B2 (en) 2017-04-25
SI2791134T1 (sl) 2020-01-31
JP2015500335A (ja) 2015-01-05
ES2960805T3 (es) 2024-03-06
DK2791134T3 (da) 2019-12-09
EP3604299A1 (en) 2020-02-05
BR112014014341A2 (pt) 2017-08-22
EP2791134A1 (en) 2014-10-22
US9126988B2 (en) 2015-09-08
PT3604299T (pt) 2023-10-31
CA2858025A1 (en) 2013-06-20
RS59666B1 (sr) 2020-01-31
CA3088684C (en) 2021-10-26
EP2791134B1 (en) 2019-09-25
EP3604299B1 (en) 2023-07-26
HRP20192133T1 (hr) 2020-02-21
JP2018052949A (ja) 2018-04-05
CY1122580T1 (el) 2021-01-27
HUE047856T2 (hu) 2020-05-28
JP6721558B2 (ja) 2020-07-15
PT2791134T (pt) 2019-12-18
ES2758659T3 (es) 2020-05-06
PL2791134T3 (pl) 2020-03-31
JP2020059729A (ja) 2020-04-16
CA3088684A1 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
JP6456143B2 (ja) カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物
TWI684593B (zh) 製備（４ｓ）-４-（４-氰基-２-甲氧基苯基）-５-乙氧基-２,８-二甲基-１,４-二氫-１,６-萘啶-３-羧醯胺之方法及其純化用於作為醫藥活性成分
CN103492361B (zh) 取代的1-苄基环烷基羧酸及其用途
CN100430384C (zh) 制备4-(4-氨基苯基)-3-吗啉酮的方法
EP2459555A1 (en) Processes for crystallization of rivaroxaban
HRP20010514A2 (en) Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
EP1590335A2 (en) Process for preparing pyrrolotriazine kinase inhibitors
AU779931B2 (en) Novel processes for making- and a new crystalline form of- leflunomide
JP2019523273A (ja) ベリノスタットの多形形態、およびその調製のためのプロセス
CN100999522B (zh) 巴马汀的制备方法
JP7478858B2 (ja) 複素環系化合物の結晶形及びその製造方法と使用
KR102323090B1 (ko) 페닐 피리미돈 화합물의 염, 다형체 및 이의 약학 조성물 및 용도
CN112390750B (zh) 作为选择性磷酸二酯酶2抑制剂的喹啉酮类化合物及其制备方法
JP2007500685A (ja) 新規の６−フェニルフェナントリジン
WO2019037161A1 (zh) 一种合成氯法齐明关键中间体n-(4-氯苯基)-1，2-苯二胺的方法
JP2009513582A (ja) ４−オキソ−１−（３置換フェニル）−１，４−ジヒドロ−１，８−ナフチリジン−３−カルボキサミドホスホジエステラーゼ４阻害剤及びその製造方法
GGL pharmacokinetie or pharmacodynamic properties, or to clinical efficiency or safety.
CN101921194A (zh) 一种制备4-氯二苯甲胺的方法
JP6147432B2 (ja) サルポグレラート塩酸塩のｉｉ型結晶の製造方法
CN109280028B (zh) 喹啉类化合物及其在dpp-4酶抑制剂的应用
HK40099431A (zh) 一种化合物的制备方法及其纯化以用作活性药物成分
HK40100474A (zh) 一种化合物的制备方法及其纯化以用作活性药物成分
HK40099449A (zh) 一种化合物的制备方法及其纯化以用作活性药物成分
HK40099449B (zh) 一种化合物的制备方法及其纯化以用作活性药物成分
EP1713769B1 (en) Amorphous tamsulosin hydrochloride

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140819

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151211

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170112

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170615

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180907

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181218

R150 Certificate of patent or registration of utility model

Ref document number: 6456143

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250